Xencor, Inc. (NASDAQ:XNCR) – Stock analysts at Leerink Swann dropped their Q3 2017 EPS estimates for Xencor in a research note issued on Tuesday. Leerink Swann analyst M. Schmidt now forecasts that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, down from their prior estimate of ($0.20). Leerink Swann also issued estimates for Xencor’s Q4 2017 earnings at ($0.24) EPS and FY2017 earnings at ($0.94) EPS.

Other equities analysts have also issued reports about the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a research report on Friday, June 16th. Finally, Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Xencor presently has an average rating of “Buy” and an average target price of $29.33.

WARNING: “Q3 2017 Earnings Forecast for Xencor, Inc. Issued By Leerink Swann (XNCR)” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/q3-2017-earnings-forecast-for-xencor-inc-issued-by-leerink-swann-xncr/1467975.html.

Shares of Xencor (NASDAQ:XNCR) opened at 22.40 on Thursday. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of 63.46 and a beta of 2.14. The stock has a 50 day moving average of $22.66 and a 200-day moving average of $23.07. Xencor has a 52 week low of $18.45 and a 52 week high of $29.38.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The firm had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million.

A number of institutional investors have recently modified their holdings of the company. Equitec Specialists LLC acquired a new position in shares of Xencor during the second quarter valued at $116,000. SG Americas Securities LLC increased its position in shares of Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the period. Airain ltd acquired a new position in shares of Xencor during the first quarter valued at $213,000. Legal & General Group Plc increased its position in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the period. Finally, Algert Global LLC acquired a new position in shares of Xencor during the first quarter valued at $284,000. Institutional investors own 74.12% of the company’s stock.

In related news, Director Bruce L. A. Carter sold 12,400 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $22.19, for a total value of $275,156.00. Following the completion of the transaction, the director now directly owns 83,344 shares of the company’s stock, valued at approximately $1,849,403.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce L. A. Carter sold 2,366 shares of the stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $22.00, for a total transaction of $52,052.00. Following the completion of the transaction, the director now directly owns 68,578 shares of the company’s stock, valued at $1,508,716. The disclosure for this sale can be found here. Insiders sold a total of 34,766 shares of company stock valued at $739,408 over the last ninety days. 4.03% of the stock is currently owned by insiders.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.